Duality Biologics and BioNTech Share Promising Results from BNT324/DB-1311 Clinical Trials at ESMO Asia 2024 Recent findings from Duality Biologics and BioNTech reveal BNT324/DB-1311's efficacy in treating advanced solid tumors, showcasing a favorable safety profile.

Duality Biologics and BioNTech Share Promising Results from BNT324/DB-1311 Clinical Trials at ESMO Asia 2024 #China #Suzhou #Duality_Biologics #BioNTech #BNT324

Duality Biologics and GSK Strike Exclusive Deal for Innovative Cancer Therapy Duality Biologics has entered into a crucial agreement with GSK for a promising antibody-drug conjugate, DB-1324, aimed at treating gastrointestinal cancers.

Duality Biologics and GSK Strike Exclusive Deal for Innovative Cancer Therapy #United_States #Duality_Biologics #Princeton #GSK #DB-1324

Duality Biologics and Adcendo ApS Strengthen Collaborative Efforts for Cancer Treatment Advancements Duality Biologics has expanded its collaboration with Adcendo ApS to enhance their groundbreaking antibody-drug conjugate (ADC) pipeline, focusing on novel treatments for cancer.

Duality Biologics and Adcendo ApS Strengthen Collaborative Efforts for Cancer Treatment Advancements #United_States #Duality_Biologics #Adcendo_ApS #antibody-drug_conjugate #Princeton